(Reuters) - Philip Morris International Inc (PM.N) should not be allowed to claim that its iQOS electronic tobacco device can reduce the risks of tobacco-related diseases for smokers who completely switch from cigarettes, a U.S. Food and Drug Administration advisory panel concluded on Thursday. The panel voted 8-0 with one abstention that the company has not conclusively demonstrated that the product reduces the risk of disease.